obinutuzumab,atezolizumab,venetoclax
roche
['obinu', 'lymsm', 'atezo', 'leusm']
molto trial: ven + atezo + obinu in untreated richter #17icml
- 28 pts
- orr 68% with mdor 26 mos (!!!)
- mpfs 16 mos, mos 32 mos
- no tls, 2 iraes, 2 gr5 aes
- reportedly no diff in response for tp53 or myc
promising option for poor prognosis disease. #lymsm #leusm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈